We provide services through several facility sites and in collaboration with a network of key partners, enabling us to scale our offerings to meet the needs of our sponsors. For information about any of our services, sites, or delivery methods, please contact us.


  • Boston Headquarters and Laboratory

    inviCRO is operated out of our Boston Innovation District headquarters. Our contract research, image analysis, and software teams work closely with the scientists in our adjacent advanced preclinical imaging laboratory, from which we execute in vivo and ex vivo small animal imaging studies in addition to radiochemistry, pharmacology, and autoradiography services. 
  • The Translational Imaging Center

    Co-managed by inviCRO and MPI Research, the TIC is located on the campus of MPI Research in Mattawan, MI. The TIC represents a combination of integrated imaging solutions offered by comprehensive imaging services in a single location and leveraging the strengths of each partner: inviCRO’s molecular imaging informatics team and radiopharmaceutical group, and MPI Research’s comprehensive CRO services.
    The world’s first commercially-available cyclotron immediately contiguous with on-site vivarium facilities permits
    drug radiolabeling with short-lived isotopes and in-depth studies across a wide variety of animal models. Additional capabilities include but are not limited to all major in vivo imaging modalities: SPECT, PET, MRI, CT, Optical, DEXA, X-ray, Laser Doppler, and Ultrasonography. Complimentary assays are offered for in vivo imaging, ex vivo distrubution, animal model development and histology, 2D GLP-compliant and 3D autoradiography, and QWBA, all supported by comprehensive and collaborative scientific expertise.
  • Queen Mary London

    Queen Mary University of London is the home laboratory of inviCRO, Ltd’s research scientists, located on the Charterhouse Square campus. inviCRO’s unique access to QMUL’s leading radiochemistry and imaging facility allows us to increase our service capacity and capabilities, particularly for our European customers. The facility has specialized hot-labs for synthesis of PET, SPECT and therapeutic radiochemicals and is fully equipped for radiopharmaceutical development and complimentary in vitro assays and autoradiography analysis. Pre-clinical imaging modalities include SPECT, PET, CT, Optical, Ultrasound and low-field MRI on rodents, and further in vivo capabilities include animal model development and access to other specialized techniques. Radiochemistry services are provided in partnership with Professor Stephen Mather.
  • New Haven: Molecular NeuroImaging (MNI), a division of inviCRO

    MNI Building inviCRO’s clinical services are delivered through MNI (Molecular NeuroImaging), a division of inviCRO. The team of scientists are recognized leaders in neurological-focused imaging and drug development and execute their work through multiple facilities, including a medicinal chemistry lab for tracer development, cGMP Radiochemistry lab for radioligand production and distribution, and an image processing lab that supports multisite coordination, site training and oversight, and data transfer management. Read more about our clinical resources here.

Partnerships and Collaborations


  • MedChem Imaging

    MedChem Imaging designs imaging probes for clients engaged in pharmaceutical research and development. These agents can be radioactive drug candidates or bind targets whose occupancy assists in understanding drug action. MedChem Imaging also supplies specialty materials to the radiopharmaceutical industry.
  • Collaborations

    In addition to those listed above, inviCRO works with a network of qualified partners across the world, allowing us to scale our service offerings across a wide range to meet specific needs.

Software Partners and Distributors


inviCRO’s software is sold and distributed by our partners world-wide. VivoQuant™, inviCRO’s multi-modality post-processing suite for viewing and analyzing imaging data and iPACS®, inviCRO’s image study data management platform for nonclinical to clinical applications, is currently used at more than 175 sites around the world and at more than 70% of the top pharmaceutical companies. inviCRO could not support our customers worldwide without the amazing efforts by our partners.

ASPECT

AXT

Bruker

Cubresa

MagneticInsight

Mediso

MedisoaUSA

Molecubes

MedisoaUSA

Sofie Biosciences

Trifoil

Trifoil